South Africa to expand rollout of new TB testing machine, but concerns remain about capacity issues

"South Africa will expand its rollout of GeneXpert tuberculosis (TB) testing machines, which can diagnose TB and drug-resistant TB within 90 minutes, but concerns remain about the capacity to back up this commitment with supplies and treatment," IRIN reports. "At the opening of the TB Vaccines Third Global Forum in Cape Town on 25 March, Precious Matsoso, director general of the South African Department of Health, announced that an additional 135 machines will be imported by the end of 2013," the news service notes, adding, "The GeneXpert was released in 2010 and South Africa already has 150." The news service notes, "Matsoso also announced that the health department, the National Department of Science and Technology, and the U.S.-based non-profit TB vaccine developer, Aeras, would continue to fund the recently created South Africa Consortium on TB Vaccine."

However, "South African AIDS lobby the Treatment Action Campaign (TAC) and international medical humanitarian organization Médecins Sans Frontières (MSF) have questioned the government's ability to deliver on these promises as stockouts and slow decentralization persist," IRIN writes, adding, "In a joint letter delivered to South African Minister of Health Dr. Aaron Motsoaledi on 22 March, the organizations stressed that the success of the GeneXpert rollout hinged on a steady supply of testing cartridges for the machines, the decentralization of drug-resistant TB (DR-TB) care and treatment, and improved supply-chain management to avoid recurring drug stockouts." The news service notes, "The country is the largest buyer of GeneXpert technology in the world, but the machines have not yet become point-of-care tests and are often deployed at district rather than clinic level" (3/26). 


http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

 

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
RSV vaccine reduces illness and hospitalizations in adults over 60